English

Turnstone Biologics Corp.

EDGAR

TSBX Quarterly report (10-Q) · filed 2025-08-08

10 filing records in this dataset, filed from 2023-06-12 to 2025-08-08. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2023 Q4 · USD

Exact inputs and evidence

Revenue: 19306000 USD Source
Revenue: 19306000 USD Source

Operating cash flow

-15.5 million USD

2023 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -66152000 USD Source
Operating Cash Flow: -50648000 USD Source

Free cash flow

-15.5 million USD

2023 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -66152000 USD Source
Operating Cash Flow: -50648000 USD Source
Capital Expenditure: 1249000 USD Source
Capital Expenditure: 1249000 USD Source

Cash and cash equivalents: 16.7 million USD 2025-06-30 Source
Exact value

16700000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 23.1 million shares 2025-06-30 Source
Exact value

23140691 shares

Reported share-count change

0.05% · 12.2 thousand shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

23128454 shares · 2024-06-30· Source
23140691 shares · 2025-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

19.3 million USD

2023-01-01 – 2023-12-31

Exact inputs and evidence

Revenue: 19306000 USD · 2023-01-01 – 2023-03-31 Source
Revenue: 19306000 USD · 2023-01-01 – 2023-06-30 Source
Revenue: 19306000 USD · 2023-01-01 – 2023-03-31 Source
Revenue: 19306000 USD · 2023-01-01 – 2023-09-30 Source
Revenue: 19306000 USD · 2023-01-01 – 2023-06-30 Source
Revenue: 19306000 USD · 2023-01-01 – 2023-12-31 Source
Revenue: 19306000 USD · 2023-01-01 – 2023-09-30 Source

Net income

-47.1 million USD

2024-07-01 – 2025-06-30

Exact inputs and evidence

Net income: -17032000 USD · 2024-07-01 – 2024-09-30 Source
Net income: -70800000 USD · 2024-01-01 – 2024-12-31 Source
Net income: -58000000 USD · 2024-01-01 – 2024-09-30 Source
Net income: -11806000 USD · 2025-01-01 – 2025-03-31 Source
Net income: -5490000 USD · 2025-04-01 – 2025-06-30 Source

Operating cash flow

-45.4 million USD

2024-07-01 – 2025-06-30

Exact inputs and evidence

Operating cash flow: -50962000 USD · 2024-01-01 – 2024-09-30 Source
Operating cash flow: -33385000 USD · 2024-01-01 – 2024-06-30 Source
Operating cash flow: -67438000 USD · 2024-01-01 – 2024-12-31 Source
Operating cash flow: -50962000 USD · 2024-01-01 – 2024-09-30 Source
Operating cash flow: -7091000 USD · 2025-01-01 – 2025-03-31 Source
Operating cash flow: -11395000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -7091000 USD · 2025-01-01 – 2025-03-31 Source

Capital expenditure

508 thousand USD

2023-07-01 – 2024-06-30

Exact inputs and evidence

Capital expenditure: 1249000 USD · 2023-01-01 – 2023-09-30 Source
Capital expenditure: 990000 USD · 2023-01-01 – 2023-06-30 Source
Capital expenditure: 1249000 USD · 2023-01-01 – 2023-12-31 Source
Capital expenditure: 1249000 USD · 2023-01-01 – 2023-09-30 Source
Capital expenditure: 144000 USD · 2024-01-01 – 2024-03-31 Source
Capital expenditure: 249000 USD · 2024-01-01 – 2024-06-30 Source
Capital expenditure: 144000 USD · 2024-01-01 – 2024-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2025-08-08.

Financial data available through: 2023-12-31.

Financial coverage is incomplete. Newer filings are recorded, but comparable financial figures for those periods are not available here yet.

Coverage by financial measure

Revenue: 2 of 11 periods available· newest 2023-12-31
Operating income: 2 of 11 periods available· newest 2023-12-31
Net income: 2 of 11 periods available· newest 2023-12-31
Operating cash flow: 2 of 11 periods available· newest 2023-12-31
Capital expenditure: 2 of 11 periods available· newest 2023-12-31
Total assets: 2 of 11 periods available· newest 2023-12-31
Total liabilities: 2 of 11 periods available· newest 2023-12-31
Current assets: 2 of 11 periods available· newest 2023-12-31
Current liabilities: 2 of 11 periods available· newest 2023-12-31
Cash and cash equivalents: 2 of 11 periods available· newest 2023-12-31
long term debt: No compatible figures in this window
Shares outstanding: 2 of 11 periods available· newest 2023-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-73.7%

Prior period

USD 73.3 million

2022-01-01 – 2022-12-31
Current period

USD 19.31 million

2023-01-01 – 2023-12-31

Exact inputs and evidence

19306000 − 73300000 = -53994000 USD

73300000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
19306000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Turnstone Biologics Corp. · 2023-12-31 Turnstone Biologics Corp. (edgar:1764974) Year-over-year change in Revenue: -53994000 USD Concept: fundies:Revenue Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1764974?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 19306000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764974/000095017025047111/tsbx-20241231.htm#1365340 Filing: 000095017025047111 Input fundies:Revenue: 73300000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764974/000095017024034974/tsbx-20231231.htm#1779387 Filing: 000095017024034974
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 24.4 million

Prior period

−USD 30.8 million

2022-01-01 – 2022-12-31
Current period

−USD 55.2 million

2023-01-01 – 2023-12-31

Exact inputs and evidence

-55200000 − -30800000 = -24400000 USD

-30800000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
-55200000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Turnstone Biologics Corp. · 2023-12-31 Turnstone Biologics Corp. (edgar:1764974) Year-over-year change in Net income: -24400000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1764974?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -55200000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764974/000095017025047111/tsbx-20241231.htm#1746385 Filing: 000095017025047111 Input fundies:NetIncome: -30800000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764974/000095017024034974/tsbx-20231231.htm#2231330 Filing: 000095017024034974
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 4.91 million

Prior period

−USD 71.06 million

2022-01-01 – 2022-12-31
Current period

−USD 66.15 million

2023-01-01 – 2023-12-31

Exact inputs and evidence

-66152000 − -71062000 = 4910000 USD

-71062000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
-66152000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Turnstone Biologics Corp. · 2023-12-31 Turnstone Biologics Corp. (edgar:1764974) Year-over-year change in Operating cash flow: 4910000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1764974?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -66152000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764974/000095017025047111/tsbx-20241231.htm#1633850 Filing: 000095017025047111 Input fundies:OperatingCashFlow: -71062000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764974/000095017024034974/tsbx-20231231.htm#2153527 Filing: 000095017024034974
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-75.8%

Prior period

USD 5.17 million

2022-01-01 – 2022-12-31
Current period

USD 1.25 million

2023-01-01 – 2023-12-31

Exact inputs and evidence

1249000 − 5170000 = -3921000 USD

5170000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
1249000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Turnstone Biologics Corp. · 2023-12-31 Turnstone Biologics Corp. (edgar:1764974) Year-over-year change in Capital expenditure: -3921000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1764974?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 1249000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764974/000095017025047111/tsbx-20241231.htm#1650935 Filing: 000095017025047111 Input fundies:CapitalExpenditure: 5170000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764974/000095017024034974/tsbx-20231231.htm#2166980 Filing: 000095017024034974
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2023 2023-01-01 – 2023-12-31

Revenue USD 19.31 million 100% of revenue
Operating costs Derived USD 78.34 million 406% of revenue
Operating income −USD 59.03 million −306% of revenue
Tax, interest and other Derived −USD 3.83 million −20% of revenue
Net income −USD 55.2 million −286% of revenue

Cash

Operating cash flow −USD 66.15 million −343% of revenue
Capital expenditure USD 1.25 million 6.5% of revenue
Free cash flow Derived −USD 67.4 million −349% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2022 Operating loss: operating costs were 143% of revenue.
2023 Operating loss: operating costs were 406% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2022 2022-01-01 – 2022-12-31	73300000	104926000 Derived	-31626000	-826000 Derived	-30800000	-76232000 Derived	Source 2022-01-01 – 2022-12-31: 73300000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -31626000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -30800000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -71062000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 5170000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	19306000	78338000 Derived	-59032000	-3832000 Derived	-55200000	-67401000 Derived	Source 2023-01-01 – 2023-12-31: 19306000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -59032000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -55200000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -66152000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 1249000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 19.3M 2023

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20222022-12-31	Revenue	73300000	Revenue: 73300000 Open source
20232023-12-31	Revenue	19306000	Revenue: 19306000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-73.7% 2023

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20222022-12-31	Year over year	No prior comparable period	Revenue: 73300000 Open source
20232023-12-31	Year over year	-73.7%	Revenue: 19306000 Open source Revenue: 73300000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -305.8% 2023

Net margin -285.9% 2023

Free cash flow margin -349.1% 2023

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20222022-12-31	Operating margin	-43.1%	Operating Income: -31626000 Open source Revenue: 73300000 Open source
20232023-12-31	Operating margin	-305.8%	Operating Income: -59032000 Open source Revenue: 19306000 Open source
20222022-12-31	Net margin	-42%	Net Income: -30800000 Open source Revenue: 73300000 Open source
20232023-12-31	Net margin	-285.9%	Net Income: -55200000 Open source Revenue: 19306000 Open source
20222022-12-31	Free cash flow margin	-104%	Revenue: 73300000 Open source Operating Cash Flow: -71062000 Open source Capital Expenditure: 5170000 Open source
20232023-12-31	Free cash flow margin	-349.1%	Revenue: 19306000 Open source Operating Cash Flow: -66152000 Open source Capital Expenditure: 1249000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -66.2M 2023

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20222022-12-31	Operating cash flow	-71062000	Operating Cash Flow: -71062000 Open source
20232023-12-31	Operating cash flow	-66152000	Operating Cash Flow: -66152000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -67.4M 2023

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20222022-12-31	Free cash flow	-76232000	Operating Cash Flow: -71062000 Open source Capital Expenditure: 5170000 Open source
20232023-12-31	Free cash flow	-67401000	Operating Cash Flow: -66152000 Open source Capital Expenditure: 1249000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

12.5% 2023

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20222022-12-31	Liabilities / assets	38.7%	Total Liabilities: 44461000 Open source Total Assets: 114938000 Open source
20232023-12-31	Liabilities / assets	12.5%	Total Liabilities: 14148000 Open source Total Assets: 112815000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

8.57× 2023

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20222022-12-31	Current assets / current liabilities	2.81×	Current Assets: 98001000 Open source Current Liabilities: 34827000 Open source
20232023-12-31	Current assets / current liabilities	8.57×	Current Assets: 102554000 Open source Current Liabilities: 11970000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2022 2022-01-01 – 2022-12-31	−USD 30.8 million Exact value Exact value: -30800000 USD 2022-01-01 – 2022-12-31: -30800000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Turnstone Biologics Corp. · 2022-12-31 Turnstone Biologics Corp. (edgar:1764974) Net Income: -30800000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1764974/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -30800000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764974/000095017024034974/tsbx-20231231.htm#2231330 Filing: 000095017024034974 The citation records this snapshot. The page link may show a newer release later.	−USD 71.06 million Exact value Exact value: -71062000 USD 2022-01-01 – 2022-12-31: -71062000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Turnstone Biologics Corp. · 2022-12-31 Turnstone Biologics Corp. (edgar:1764974) Operating Cash Flow: -71062000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1764974/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -71062000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764974/000095017024034974/tsbx-20231231.htm#2153527 Filing: 000095017024034974 The citation records this snapshot. The page link may show a newer release later.	USD 5.17 million Exact value Exact value: 5170000 USD 2022-01-01 – 2022-12-31: 5170000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Turnstone Biologics Corp. · 2022-12-31 Turnstone Biologics Corp. (edgar:1764974) Capital Expenditure: 5170000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1764974/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 5170000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764974/000095017024034974/tsbx-20231231.htm#2166980 Filing: 000095017024034974 The citation records this snapshot. The page link may show a newer release later.	−USD 76.23 million Calculation and evidence -71062000 − 5170000 USD Exact free cash flow: -76232000 USD 2022-01-01 – 2022-12-31: -71062000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 5170000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Turnstone Biologics Corp. · 2022-12-31 Turnstone Biologics Corp. (edgar:1764974) Free cash flow: -76232000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1764974?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -71062000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764974/000095017024034974/tsbx-20231231.htm#2153527 Filing: 000095017024034974 Input fundies:CapitalExpenditure: 5170000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764974/000095017024034974/tsbx-20231231.htm#2166980 Filing: 000095017024034974 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 55.2 million Exact value Exact value: -55200000 USD 2023-01-01 – 2023-12-31: -55200000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Turnstone Biologics Corp. · 2023-12-31 Turnstone Biologics Corp. (edgar:1764974) Net Income: -55200000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1764974/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -55200000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764974/000095017025047111/tsbx-20241231.htm#1746385 Filing: 000095017025047111 The citation records this snapshot. The page link may show a newer release later.	−USD 66.15 million Exact value Exact value: -66152000 USD 2023-01-01 – 2023-12-31: -66152000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Turnstone Biologics Corp. · 2023-12-31 Turnstone Biologics Corp. (edgar:1764974) Operating Cash Flow: -66152000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1764974/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -66152000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764974/000095017025047111/tsbx-20241231.htm#1633850 Filing: 000095017025047111 The citation records this snapshot. The page link may show a newer release later.	USD 1.25 million Exact value Exact value: 1249000 USD 2023-01-01 – 2023-12-31: 1249000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Turnstone Biologics Corp. · 2023-12-31 Turnstone Biologics Corp. (edgar:1764974) Capital Expenditure: 1249000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1764974/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1249000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764974/000095017025047111/tsbx-20241231.htm#1650935 Filing: 000095017025047111 The citation records this snapshot. The page link may show a newer release later.	−USD 67.4 million Calculation and evidence -66152000 − 1249000 USD Exact free cash flow: -67401000 USD 2023-01-01 – 2023-12-31: -66152000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 1249000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Turnstone Biologics Corp. · 2023-12-31 Turnstone Biologics Corp. (edgar:1764974) Free cash flow: -67401000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T17:15:30Z Snapshot: 8584cf069903416cc41881e8af308f4ab433f886df7f9fc24a8aea8744c83009 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1764974?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -66152000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764974/000095017025047111/tsbx-20241231.htm#1633850 Filing: 000095017025047111 Input fundies:CapitalExpenditure: 1249000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1764974/000095017025047111/tsbx-20241231.htm#1650935 Filing: 000095017025047111 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

10 filings · 731 latest values · 731 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001764974, 1764974, TSBX, edgar:1764974

Also known as Turnstone Biologics Corp.

Turnstone Biologics Corp.

Latest quarter

Revenue

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2023 2023-01-01 – 2023-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation